Gladius Capital Management’s Lunai Bioworks LNAI Stock Holding History

Gladius Capital Management’s Portfolio LNAI Stock Details LNAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-190	Closed	-$28K	–	424
2022 Q3	$28K	Buy	+190	New	+$34.6K	﹤0.01%	316

Other funds holding LNAI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Gladius Capital Management's LNAI Position: Q4 2022 in Review

Gladius Capital Management sold out of Lunai Bioworks (LNAI) in Q4 2022, closing a stake of 190 shares — an estimated $28K sold.

Gladius Capital Management first reported a position in LNAI in Q3 2022 and held it in 1 quarter. The position peaked at $28K in Q3 2022. 36 funds tracked by Wall St. Rank hold LNAI as of Q4 2022.

Gladius Capital Management reported no remaining Lunai Bioworks position as of Q4 2022 after selling out during the quarter.
Gladius Capital Management sold 190 Lunai Bioworks shares in Q4 2022, an estimated $28K.
Gladius Capital Management first reported a position in Lunai Bioworks in Q3 2022 and held it in 1 quarter.
Gladius Capital Management's Lunai Bioworks position peaked at $28K in Q3 2022.
36 funds tracked by Wall St. Rank held Lunai Bioworks as of Q4 2022.

Based on Gladius Capital Management's 13F filing for Q4 2022, filed 2 Feb 2023.